Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 August;157(4) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 August;157(4):105-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 August;157(4):105-9

Copyright © 1998 EDIZIONI MINERVA MEDICA

language: English

Effect of treatment of postmenopausal osteoporosis with continuous daily oral alendronate and the incidence of fractures

Carfora E. 1, Sergio F. 2, Bellini P. 1, Sergio C. 3, Falco D. 2, Zarcone R. 1

1 Second University of Naples, Department of Obstetrics and Gynaecology; 2 Second University of Naples, Department of Orthopaedy and Traumatology; 3 Second University of Naples, Department of Biochemistry


PDF


Back­ground. Alen­dro­nate is a ­potent ami­no­bi­sphos­pho­nate ­which spe­cif­i­cally ­inhibits oste­o­clastic ­bone resorp­tion and has ­been ­found to ­reserve ­bone ­loss. The aim of ­this ­study is to deter­mine if ­daily ­oral alen­dro­nate treat­ment ­could pre­vent or ­reserve ­bone ­loss in oste­op­o­rotic post­men­o­pausal ­women.
­Methods. ­Between ­December 1993 and May 1996 we ­have ­studied, at the ­Obstetric and Gy-nae­co­logic ­Clinic of II Uni­ver­sity of ­Naples, 136 ­women, 44-73 ­aged, in ­postmen­o­pause ­from 5 ­years, ­with oste­o­por­osis (­defined as a ­bone min­eral den­sity of the ­lumbar ­spine ­that was at ­least 2.5 SD ­below the ­mean ­value in pre-men­o­pausal ­women).
­Bone min­eral den­sity was meas­ured by ­dual-­energy X-ray absorp­tiom­etry. ­During ­this ­period of two and ­half ­years of obser­va­tion, the ­effects of alen­dro­nate ­were mon­i­tored on the bio­chem­ical indi­ca­tors of ­bone remod­el­ment and on the metab­olism of the cal­cium; the ­degree of cer­tainty and tol­er­ability of ­this ­drug has ­also ­been ­assessed.
­Results. The ­women ­receiving alen­dro­nate had sig­nif­i­cant, pro­gres­sive ­increases in ­bone min­eral den­sity in the ­spine, ­whereas ­those ­receiving pla­cebo had ­decreases in ­bone min­eral den­sity.
The rel­a­tive ­risk of a new frac­ture ­among the ­women ­treated ­with alen­dro­nate, as com­pared ­with ­those ­receiving pla­cebo, was 0.55.
Con­clu­sions. The ­therapy ­with alen­dro­nate has, on the ­basis of ­data pro­posed ­from ­this ­study, a ­good tol­er­ability and is ­very effec­tive in the treat­ment of ­postmen­o­pausal oste­o­por­osis.

top of page